There are currently 234 clinical trials in Hartford, Connecticut looking for participants to engage in research studies. Trials are conducted at various facilities, including Hartford Hospital, Connecticut Children's Medical Center, Smilow Cancer Hospital Care Center at Saint Francis and Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
NCT04973137
Recruiting
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: St. Francis Hospital, Hartford, Connecticut
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
Utility of PCD Diagnostics to Improve Clinical Care
NCT05889013
Recruiting
This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnos... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
09/26/2024
Locations: Pulmonary Division, Hartford, Connecticut
Conditions: Primary Ciliary Dyskinesia
Register for Updates
M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study
NCT04982835
Recruiting
Prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/20/2024
Locations: Hartford Healthcare Bone & Joint Institute, Hartford, Connecticut
Conditions: Cervical Disc Degenerative Disorder
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: Neuroblastoma
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: Hartford Healthcare, Hartford, Connecticut
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
Strengthening the Connections to Opportunities for Prevention Engagement
NCT06442046
Recruiting
The Strengthening the Connections to Opportunities for Prevention Engagement (SCOPE) project will create a pathway for children and families from the City of Hartford to connect with a Connecticut Children's Care Coordinator (CC) in an effort to reduce levels of violence exposure.
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
09/04/2024
Locations: Connecticut Children's, Hartford, Connecticut
Conditions: Interpersonal Violence, Structural Violence
Register for Updates
CLOZAPINE Response in Biotype-1
NCT04580134
Recruiting
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/27/2024
Locations: Hartford Healthcare, Hartford, Connecticut
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/21/2024
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: Neuroblastoma
Register for Updates
Impact of Family-Centered Care for Intimate Partner Violence (IPV)
NCT06071299
Recruiting
The purpose of the study will be to determine how participation in Family-Centered Care (FCC) compared to Child-centered care (CCC) will affect caregiver engagement in IPV-based community services, caregiver perceptions of empowerment and survivor-defined practice, and clinical outcomes for children exposed to IPV.
Gender:
ALL
Ages:
3 years and below
Trial Updated:
08/13/2024
Locations: SCAN Clinic, Hartford, Connecticut
Conditions: Intimate Partner Violence
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Hartford Hospital, Hartford, Connecticut +1 locations
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
08/02/2024
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: Neuroblastoma
Register for Updates